FirstLine – Newsemia

Pembrolizumab Gets First-Line Indication for mCRC

NewsemiaJune 30, 2020

by NewsemiaJune 30, 202000

(MedPage Today) — WASHINGTON — The FDA approved the PD-1 inhibitor pembrolizumab (Keytruda) as initial treatment of metastatic, mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) colorectal...

Gastroenterology

Comparison of efficacy and health-related quality of life of first-line haploidentical hematopoietic stem cell transplantation with unrelated cord blood infusion and first-line immunosuppressive therapy for acquired severe aplastic anemia

NewsemiaJune 26, 2020

by NewsemiaJune 26, 202000

Comparison of efficacy and health-related quality of life of first-line haploidentical hematopoietic stem cell transplantation with unrelated cord blood infusion and first-line immunosuppressive therapy for...

Gastroenterology

FDA OKs First-Line Immunotherapy in Liver Cancer

NewsemiaJune 1, 2020

by NewsemiaJune 1, 202001

<![CDATA[]]>(MedPage Today) — The FDA on Friday approved the PD-L1 immune checkpoint inhibitor atezolizumab (Tecentriq) for the first-line treatment of unresectable or metastatic liver cancer,...

Gastroenterology

First-Line Win for Anti-PD-1 Drug in Advanced Colon Cancer

NewsemiaMay 30, 2020

by NewsemiaMay 30, 202003

<![CDATA[]]>(MedPage Today) — Patients with untreated heavily mutated metastatic colorectal cancer (mCRC) lived twice as long without disease progression when they received an immune checkpoint...

Pharma / Biotech

Opdivo-Yervoy Approved as First-Line Rx With Chemo for Some Metastatic NSCLC Patients

NewsemiaMay 30, 2020

by NewsemiaMay 30, 202005

The FDA approved use of the combination of nivolumab (Opdivo, Bristol-Myers Squibb) and ipilimumab (Yervoy, Bristol-Myers Squibb), along with two cycles of platinum-doublet chemotherapy, for...

Gastroenterology

OncMadness: Round 4, First-Line 4

NewsemiaMay 28, 2020

by NewsemiaMay 28, 202004

<![CDATA[]]>(MedPage Today) — The fourth round of voting in OncMadness 2020 is over — welcome to the First-Line 4. Let’s check out where things stand...

Pharma / Biotech

FDA Grants New First-Line Indications to 3 Targeted Therapies for Metastatic NSCLC

NewsemiaMay 21, 2020

by NewsemiaMay 21, 2020030

The regimens were approved as first-line treatment for patients with metastatic NSCLC whose tumors express PD-L1 (≥1%) with no epidermal growth factor receptor (EGFR) or anaplastic...

Gastroenterology

A New First-Line Treatment Regimen for H. pylori Infection

NewsemiaMay 19, 2020

by NewsemiaMay 19, 202006

Phase III trial findings are reported for a recently approved rifabutin-based triple therapy. Source link...

Gastroenterology

The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials

NewsemiaMay 19, 2020

by NewsemiaMay 19, 202007

The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials Source link...

Neurology

Evaluation of efficacy and tolerability of first-line therapies in NMOSD

NewsemiaApril 15, 2020

by NewsemiaApril 15, 202003

Objective To compare the efficacy and the risk of severe infectious events of immunosuppressive agents used early as first-line therapy in patients with neuromyelitis optica...

FDA grants priority review to first-line lung cancer regimen

NewsemiaApril 12, 2020

by NewsemiaApril 12, 2020029

The FDA granted priority review to nivolumab plus ipilimumab combined with a limited chemotherapy course as first-line treatment for patients with metastatic or recurrent non-small...

Pharma / Biotech

Imfinzi Approved for First-Line Treatment of Extensive-Stage SCLC

NewsemiaApril 7, 2020

by NewsemiaApril 7, 2020030

The FDA approved durvalumab (Imfinzi, AstraZeneca) in combination with etoposide and either carboplatin or cisplatin as first-line treatment of patients with extensive-stage small cell lung...

First-line psychotherapies show limited effectiveness for treating military-related PTSD

NewsemiaFebruary 4, 2020

by NewsemiaFebruary 4, 2020032

A review of recent clinical trials paints a sobering picture of the usefulness of first-line psychotherapies in treating active duty military personnel and veterans with...

Gastroenterology

First-Line IO Yields Long Survival in MSI-H/dMMR Colon Cancer

NewsemiaJanuary 29, 2020

by NewsemiaJanuary 29, 2020021

<![CDATA[]]>(MedPage Today) — SAN FRANCISCO — The scientific program of the Gastrointestinal Cancers Symposium included more than 800 abstracts over the three days of the...

Pharma / Biotech

Oral vinorelbine versus intravenous vinorelbine, in combination with epirubicin as first-line chemotherapy in Chinese patients with metastatic breast cancer.

NewsemiaDecember 16, 2019

by NewsemiaDecember 16, 201905

Related Articles Oral vinorelbine versus intravenous vinorelbine, in combination with epirubicin as first-line chemotherapy in Chinese patients with metastatic breast cancer. Cancer Chemother Pharmacol. 2019...

Gastroenterology

Anti-TNF therapy appears effective after first-line Entyvio in IBD

NewsemiaDecember 9, 2019

by NewsemiaDecember 9, 201907

SAN ANTONIO — In patients with inflammatory bowel disease, first-line vedolizumab treatment did not appear to compromise the effectiveness of successive anti-TNF treatment in real-world...

Gastroenterology

First-Line Combo Improves Survival in Advanced HCC

NewsemiaNovember 24, 2019

by NewsemiaNovember 24, 201904

<![CDATA[]]>(MedPage Today) — For the first time in more than a decade, patients with hepatocellular carcinoma (HCC) lived significantly longer with a new upfront therapy...

Takeda Presents Long-Term Data in ALK+ NSCLC Showing ALUNBRIG® (brigatinib) Continues to Demonstrate Superiority in the First-Line After Two Years of Follow-Up

NewsemiaNovember 24, 2019

by NewsemiaNovember 24, 201904

CAMBRIDGE, Mass. & OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced updated data from the Phase 3 ALTA-1L trial, which evaluated ALUNBRIG versus crizotinib...

Pharma / Biotech

When First-Line HCC Rx Fails, What Comes Next?

NewsemiaOctober 21, 2019

by NewsemiaOctober 21, 201902

Although the emergence of sorafenib in the front-line setting for hepatocellular carcinoma (HCC) has changed practice, many clinicians continue to debate the best second-line agent...

Pharma / Biotech

A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-line Treatment for EGFR-mutation Positive NSCLC Patients.

NewsemiaOctober 18, 2019

by NewsemiaOctober 18, 201905

Related Articles A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-line Treatment for EGFR-mutation Positive NSCLC Patients. J...

Newsemia

Tag: FirstLine

Pembrolizumab Gets First-Line Indication for mCRC

Comparison of efficacy and health-related quality of life of first-line haploidentical hematopoietic stem cell transplantation with unrelated cord blood infusion and first-line immunosuppressive therapy for acquired severe aplastic anemia

FDA OKs First-Line Immunotherapy in Liver Cancer

First-Line Win for Anti-PD-1 Drug in Advanced Colon Cancer

Opdivo-Yervoy Approved as First-Line Rx With Chemo for Some Metastatic NSCLC Patients

OncMadness: Round 4, First-Line 4

FDA Grants New First-Line Indications to 3 Targeted Therapies for Metastatic NSCLC

A New First-Line Treatment Regimen for H. pylori Infection

The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials

Evaluation of efficacy and tolerability of first-line therapies in NMOSD

FDA grants priority review to first-line lung cancer regimen

Imfinzi Approved for First-Line Treatment of Extensive-Stage SCLC

First-line psychotherapies show limited effectiveness for treating military-related PTSD

First-Line IO Yields Long Survival in MSI-H/dMMR Colon Cancer

Oral vinorelbine versus intravenous vinorelbine, in combination with epirubicin as first-line chemotherapy in Chinese patients with metastatic breast cancer.

Anti-TNF therapy appears effective after first-line Entyvio in IBD

First-Line Combo Improves Survival in Advanced HCC

Takeda Presents Long-Term Data in ALK+ NSCLC Showing ALUNBRIG® (brigatinib) Continues to Demonstrate Superiority in the First-Line After Two Years of Follow-Up

When First-Line HCC Rx Fails, What Comes Next?

A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-line Treatment for EGFR-mutation Positive NSCLC Patients.

COVID-19